Intravitreal Ranibizumab in Retinal Pigment Epithelial Detachments

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to demonstrate the efficacy of ranibizumab in patients with retinal pigment epithelial detachment secondary to age-related macular degeneration (AMD).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital Muenster; University Hospital, Bonn
• Collaborator: Novartis
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

• patients with age-related macular degeneration and serous pigment epithelial detachment as determined by fluorescein and indocyanine green angiography and optical coherence tomography (OCT)

• patients who have a best-corrected visual acuity (BCVA) score between 73 and 24 ETDRS letters

• patients with pigment epithelial detachment (PED) ≥ 200 µm as determined by OCT

• male or female patients 50 years of age or greater

• patients willing and able to comply with all study procedures

Exclusion Criteria:

• patients with best-corrected visual acuity (BCVA) < 24 or >73 letters in the study eye

• patients previously treated by intravitreal injections of steroids or anti-VEGF agents, or patients previously treated by Verteporfin photodynamic therapy or focal laser photocoagulation

• history of uncontrolled glaucoma in the study eye